These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23070004)

  • 1. Targeting the anti-apoptotic Bcl-2 family members for the treatment of cancer.
    Weyhenmeyer B; Murphy AC; Prehn JH; Murphy BM
    Exp Oncol; 2012 Oct; 34(3):192-9. PubMed ID: 23070004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells.
    Arisan ED; Kutuk O; Tezil T; Bodur C; Telci D; Basaga H
    Breast Cancer Res Treat; 2010 Jan; 119(2):271-81. PubMed ID: 19238538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Bcl-2 in tumour cell survival and implications for pharmacotherapy.
    Tomek M; Akiyama T; Dass CR
    J Pharm Pharmacol; 2012 Dec; 64(12):1695-702. PubMed ID: 23146031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
    Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
    Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL-2 family isoforms in apoptosis and cancer.
    Warren CFA; Wong-Brown MW; Bowden NA
    Cell Death Dis; 2019 Feb; 10(3):177. PubMed ID: 30792387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA regulation of core apoptosis pathways in cancer.
    Lima RT; Busacca S; Almeida GM; Gaudino G; Fennell DA; Vasconcelos MH
    Eur J Cancer; 2011 Jan; 47(2):163-74. PubMed ID: 21145728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on celecoxib-induced apoptosis.
    Rudner J; Elsaesser SJ; Müller AC; Belka C; Jendrossek V
    Biochem Pharmacol; 2010 Jan; 79(1):10-20. PubMed ID: 19665451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcl-2 family proteins as targets for anticancer drug design.
    Huang Z
    Oncogene; 2000 Dec; 19(56):6627-31. PubMed ID: 11426648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions.
    Finnegan NM; Curtin JF; Prevost G; Morgan B; Cotter TG
    Br J Cancer; 2001 Jul; 85(1):115-21. PubMed ID: 11437412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pro- and anti-apoptotic members of the Bcl-2 family in skeletal muscle: a distinct role for Bcl-2 in later stages of myogenesis.
    Dominov JA; Houlihan-Kawamoto CA; Swap CJ; Miller JB
    Dev Dyn; 2001 Jan; 220(1):18-26. PubMed ID: 11146504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the Bcl-2.
    Patel MP; Masood A; Patel PS; Chanan-Khan AA
    Curr Opin Oncol; 2009 Nov; 21(6):516-23. PubMed ID: 19730103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progress in small-molecule inhibitors of Bcl-2 family proteins].
    Tang Y; Zhang DY; Wu XM
    Yao Xue Xue Bao; 2008 Jul; 43(7):669-77. PubMed ID: 18819468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737.
    Ishitsuka K; Kunami N; Katsuya H; Nogami R; Ishikawa C; Yotsumoto F; Tanji H; Mori N; Takeshita M; Miyamoto S; Tamura K
    Cancer Lett; 2012 Apr; 317(2):218-25. PubMed ID: 22138435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line.
    Fiebig AA; Zhu W; Hollerbach C; Leber B; Andrews DW
    BMC Cancer; 2006 Aug; 6():213. PubMed ID: 16928273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pro-apoptotic activity of BH3-only proteins and BH3 mimetics: from theory to potential cancer therapy.
    Hartman ML; Czyz M
    Anticancer Agents Med Chem; 2012 Oct; 12(8):966-81. PubMed ID: 22263800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
    Doshi JM; Tian D; Xing C
    J Med Chem; 2006 Dec; 49(26):7731-9. PubMed ID: 17181155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.
    Zheng CH; Yang H; Zhang M; Lu SH; Shi D; Wang J; Chen XH; Ren XH; Liu J; Lv JG; Zhu J; Zhou YJ
    Bioorg Med Chem Lett; 2012 Jan; 22(1):39-44. PubMed ID: 22172701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-apoptotic Bcl-2 fails to form efficient complexes with pro-apoptotic Bak to protect from Celecoxib-induced apoptosis.
    Rudner J; Elsaesser SJ; Jendrossek V; Huber SM
    Biochem Pharmacol; 2011 Jan; 81(1):32-42. PubMed ID: 20836993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family.
    Shangary S; Johnson DE
    Leukemia; 2003 Aug; 17(8):1470-81. PubMed ID: 12886234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide screening to knockdown Bcl-2's anti-apoptotic activity: implications in cancer treatment.
    Raghav PK; Verma YK; Gangenahalli GU
    Int J Biol Macromol; 2012 Apr; 50(3):796-814. PubMed ID: 22155216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.